Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life

Real-world evidence of radium 223 (Ra-223) for the treatment of men with metastatic castration-resistant prostate cancer is emerging. In this prospective single-centre service evaluation, we report for the first time in the UK, real-world quality of life (QoL) and survival outcomes, including the sequencing impact, in 228 treated patients. We aim to share our 5-year experience on how to optimise Ra-223 treatment.

Source: Clinical Oncology - May 20, 2020 Category: Radiology Authors: X.Y. Jiang, S. Atkinson, R. Pearson, D. Leaning, S. Cumming, A. Burns, A. Azzabi, J. Frew, R. McMenemin, I.D. Pedley Tags: Original Article Source Type: research